Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 15.02 5.40% 0.77
NTLA closed up 5.4 percent on Wednesday, January 16, 2019, on approximately normal volume.
7 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical NTLA trend table...

Date Alert Name Type % Chg
Jan 16 New Uptrend Bullish 0.00%
Jan 15 Crossed Above 20 DMA Bullish 5.40%
Jan 14 Fell Below 20 DMA Bearish 11.01%
Jan 14 Wide Bands Range Expansion 11.01%
Jan 14 Down 3 Days in a Row Weakness 11.01%
Jan 11 Narrow Range Bar Range Contraction 6.60%
Jan 11 NR7 Range Contraction 6.60%
Jan 11 NR7-2 Range Contraction 6.60%
Jan 11 Stochastic Reached Overbought Strength 6.60%
Jan 11 Weak + Overbought Other 6.60%

Older signals for NTLA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Is NTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 16 Gene editors up on promising research in parasitic diseases
Jan 15 FDA to beef up cell and gene therapy staff
Jan 11 Here's Why Intellia Therapeutics Stock Lost 23.8% in December
Jan 10 The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%
Jan 7 Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
Jan 4 These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy
Jan 3 J&J teams up with Locus Biosciences to develop CRISPR-based therapies for infections
Dec 31 Vertex ups stake in CRISPR Therapeutics to 10.4%
Dec 24 60 Biggest Movers From Friday
Dec 20 The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
See more NTLA news...
Indicators
Indicator Value
52 Week High 35.99
52 Week Low 11.03
Average Volume 681,530
200-Day Moving Average 23.4468
50-Day Moving Average 15.8148
20-Day Moving Average 13.6165
10-Day Moving Average 14.185
Average True Range 1.0422
ADX 28.77
+DI 22.3937
-DI 21.7529
Chandelier Exit (Long, 3 ATRs ) 13.0434
Chandelier Exit (Short, 3 ATRs ) 14.1566
Upper Bollinger Band 15.488
Lower Bollinger Band 11.745
Percent B (%b) 0.87
BandWidth 27.488709
MACD Line -0.426
MACD Signal Line -0.7281
MACD Histogram 0.3021
Fundamentals Value
Market Cap 542.4 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -11.29
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.78
Resistance 3 (R3) 16.72 16.09 16.48
Resistance 2 (R2) 16.09 15.64 16.11 16.38
Resistance 1 (R1) 15.55 15.36 15.82 15.61 16.29
Pivot Point 14.92 14.92 15.05 14.94 14.92
Support 1 (S1) 14.38 14.47 14.65 14.44 13.75
Support 2 (S2) 13.75 14.19 13.77 13.66
Support 3 (S3) 13.21 13.75 13.56
Support 4 (S4) 13.27